AVTX · Avalo Therapeutics, Inc.

Track AVTX — free

$11.27 -0.74 (-6.16%) At close · Oct 16

Russell 2000 member Rebalance outlook locked

Market Cap

$612.72M

53.63M

Volume · Oct 16 971.12K Avg daily vol (3M) 937.19K

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$100.33M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-123,601.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+302.6%

Year over year · more shares

Price change (1Y)

-19.5%

Trailing year

Short interest

21.3%

Latest settlement · 8.8 days to cover

View all 115 metrics

Quarterly results

Revenue Net income Net loss

▼37.8% $643,000 −$8.19M '23 Q2 ▼98.4% $236,000 −$5.23M '23 Q3 ▼36.4% $570,000 −$8.17M '23 Q4* ▼100% $0 −$121.29M '24 Q1 ▼100% $0 $98.46M '24 Q2 ▲5.5% $249,000 $23.04M '24 Q3 ▼66.3% $192,000 −$35.34M '24 Q4* LATEST ▼100% $0 −$30.62M '25 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 20 · elevated Equity put/call 0.65

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −31%

below

Price vs 50-day avg −34%

below

RSI (14) 21

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −32%

trailing

6-month return −22%

trailing

YTD return −38%

this year

Relative strength −29%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $17 › 200d $16 — 50d above 200d

Institutional flow Accumulating

6 of 127 funds reported for Sep 30 · net +265 sh shares · +4 new

Insider flow Distributing

Net -$52.0K over 90 days · 100% sells

Short interest Falling

21.27% of float · ▼ -11.8% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Strong

Revenue growth +2312%

Y/Y

EPS growth +72%

Y/Y

Free cash flow $-51.6M

Balance sheet $4.7M

net debt

Quant / Vol

risk profile

Very High

Volatility 82%

annualized · 1-yr

Max drawdown −51%

past year

ATR 7.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−31% Bearish

Price vs 50-day avg

−34% Bearish

RSI (14)

21 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $17 › 200d $16 — 50d above 200d

Institutional flow Accumulating

6 of 127 funds reported for Sep 30 · net +265 sh shares · +4 new

Insider flow Distributing

Net -$52.0K over 90 days · 100% sells

Short interest Falling

21.27% of float · ▼ -11.8% MoM · 8.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $11 Now $11 · 0% Range high $23

vs 200-day avg -31% vs 50-day avg -34%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AVTX Avalo Therapeutics, Inc. this stock	$612.72M	-37.9%	+2312.3%	—	21.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$128.95B	+10.2%	+46.2%	29.6	1.8%
MRNA Moderna, Inc.	$87.04B	+639.3%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$81.41B	+2.4%	+20.8%	19.6	2.1%
CSLLY Csl Ltd	$63.79B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

131

% held: 133.6%
Reported: 6 of 127
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

124

View

Short & Settlement

Short Interest Falling

Shares short

11.4M

Days to cover: 8.8d
Change: -1.5M sh

View

Short Volume

Short vol %

50%

As of: Oct 16, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.5K
As of: Sep 24, 2026

View

Off-Exchange

Off-exchange %

48.2%

Week of: Sep 7, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$52.0K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$59.0K

Net income (FY): $-78.3M
EPS diluted: $-5.84

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 16

View

Proposed Sales

Value

$622.2K

Shares: 31.0K
Filed: Aug 18, 2026

View

Exempt Offerings

Offering

$200.0M

Filed: Apr 9, 2024

View

Performance

	5D	20D	120D	MTD	YTD
AVTX	-17.4%	-32.0%	-21.8%	-26.5%	-37.9%
SPY	-2.0%	+0.2%	+6.7%	+0.1%	+11.9%
vs SPY	-15.5%	-32.2%	-28.6%	-26.6%	-49.9%

Key facts CIK 1534120 CUSIP 05338F306 13F (30d) 8 filings 8 filers Visit website Investor relations

AVTX · Avalo Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance